RT Journal Article SR Electronic T1 Lung volume reduction coil (LVRC) treatment is safe and effective in heterogeneous and homogeneous emphysema JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP P2289 VO 42 IS Suppl 57 A1 Gaetan Deslee A1 Stefan Blaas A1 Wolfang Gesierich A1 Felix Herth A1 Juergen Hetzel A1 Martin Hetzel A1 Romain Kessler A1 Charles Hugo Marquette A1 Michael Pfeifer A1 Franz Stanzel A1 Christian Witt A1 Dirk Jan Slebos YR 2013 UL http://erj.ersjournals.com/content/42/Suppl_57/P2289.abstract AB Rationale: The Lung Volume Reduction Coil (LVRC, PneumRx Inc.) is a bronchoscopic device for treatment of severe emphysema. Three multicenter European studies assessed the safety and efficacy of LVRC treatment in emphysema.Methods: 109 patients (mean age: 61 yrs, FEV1: 29%, RV: 242%) were treated by bilateral LVRC performed in two separate procedures. Data were analyzed at 6 and 12-months post treatment. A post-hoc blinded CT analysis was performed using a visual approach grading from 0 (minimal damage, scattered small centrilobular defects) to 4 (panlobular emphysema and complete loss of secondary lobular structure), a difference of ≤1 point defining homogeneous emphysema.Results: 2081 LVRC were placed (mean 9.5 per lobe). Serious adverse events (SAE) at 30 days following treatments were 6 % COPD exacerbations, 0.5 % haemoptysis, 5% pneumonia, 4% pneumothorax, and no death or acute respiratory failure. All SAE resolved with standard care. Changes from baseline at 6 and 12 months in heterogeneous emphysema were: FEV1 : +19.3 and +18%, RV: -9.7 and -9.6%, 6-min walking distance (6MWD): +47 and +57m, quality of life (SGRQ): -13.8 and -12.3 pts (all, p<0.0001). In homogeneous emphysema, changes from baseline at 6 and 12 months were: FEV1 : +9.8 and +12.2%, RV: -10.2 and -10.5%, 6MWD: +42 and +55m, quality of life (SGRQ): -9.4 and -9 pts (all, p<0.0001). No difference was found at 6 and 12 months between homogeneous and heterogeneous emphysema (all, p>0.05).Conclusion: LVRC treatment results in clinically relevant improvements in lung function, exercise capacity and quality of life in homogeneous and heterogeneous emphysema, with sustained improvements beyond one year.